Pediatric Bone Marrow Transplant at Acıbadem Altunizade Hospital

Acıbadem Altunizade’s Pediatric BMT Program

Acıbadem’s official materials describe pediatric autologous, matched related allogeneic, haploidentical and matched unrelated donor pathways. The supplied institutional offers are used here to explain how these pathways differ; they are not reproduced as current packages or individualized treatment plans.

Acıbadem Altunizade is the published partner program for this pathway, not the family’s only option. MedTransplant can also help families explore other verified programs or request a comparison.

What Pediatric BMT or HSCT Means

Bone marrow transplantation is commonly discussed alongside hematopoietic stem-cell transplantation, or HSCT. The treatment gives blood-forming stem cells after a conditioning regimen. Depending on the clinical plan, the cells may come from the child or from a carefully assessed donor.

The purpose, expected benefit and risks differ by diagnosis and transplant type. A website comparison cannot select the correct pathway for a child.

Specialist Evaluation Comes Before a Transplant Plan

A diagnosis such as leukemia, thalassemia or sickle-cell disease does not by itself mean a child needs transplant. The pediatric hematology team must assess the exact condition, severity, treatment response, alternatives, risks and likely benefit.

An initial records review is not a diagnosis, treatment recommendation or confirmation that transplantation is appropriate.

Conditions Require Different Decisions

Some leukemias, bone-marrow failure disorders, immune conditions, inherited blood disorders and metabolic diseases may lead a specialist team to consider HSCT in selected circumstances. Many children receive other treatments instead or first.

1. Pediatric Autologous Stem-Cell Transplant

An autologous transplant uses the child’s own stem cells. Cells are collected and stored, and later returned after the conditioning or treatment pathway. It does not use a family or registry donor and therefore differs fundamentally from allogeneic transplantation.

The supplied Acıbadem autologous offer describes pre-transplant infection, blood, organ-function, cardiac, respiratory, urine and bone-marrow assessments, followed by close blood-count and organ-function monitoring. The exact tests and timing remain case-specific.

2. Pediatric Matched Related Allogeneic Transplant

A matched related allogeneic transplant uses stem cells from a related donor whose HLA and health assessment are considered suitable by the transplant team. A sibling or other family member is not automatically a match or an acceptable donor.

The supplied Acıbadem material describes separate recipient and donor work-ups, repeat HLA compatibility testing, donor mobilization and collection, conditioning, infusion, engraftment surveillance, chimerism assessment and monitoring for infection and graft-versus-host disease (GVHD).

3. Pediatric Haploidentical Stem-Cell Transplant

Haploidentical means a partially matched related donor pathway. It may be evaluated when a fully matched donor is not available, but being a parent, sibling or relative does not establish suitability.

Acıbadem’s supplied offer describes repeat HLA assessment and additional donor/recipient screening before collection. It gives source-specific estimates of several days for suitability testing and collection and approximately ten days for a donor’s stay. These are planning estimates from the document, not guarantees or current package commitments.

4. Pediatric Matched Unrelated Donor (MUD) Transplant

When no suitable related donor is available, specialists may consider a matched unrelated donor search. The supplied Acıbadem material describes high-resolution HLA typing, a preliminary computerized search, and—if clinically appropriate—a formal search in which potential donors are contacted and confirmatory testing is arranged.

The institutional source says a search may take months and elsewhere gives a broad estimate extending from about three months to one year. This source-specific range is not a promise: registry availability, confirmatory testing, donor readiness and the child’s clinical course all affect timing. Identifying a potential match does not guarantee donor clearance, hospital acceptance or transplantation.

Donor Suitability and Child Safeguarding

A sibling, parent or other possible donor is not automatically suitable. HLA matching, donor health, consent, child safeguarding, cell source and any registry or legal requirements need separate specialist review.

MedTransplant does not find or promise donors. A potential donor requires an independent, hospital-led pathway with age-appropriate consent or authorization.

Records for Preliminary Pediatric Review

A structured file can help the hospital understand the referral question before a family travels.

• Pediatric hematology summary and confirmed diagnosis
• Pathology, bone-marrow, flow-cytometry, molecular and genetic reports
• Treatment timeline, response and complications
• Recent blood counts, organ-function and infection results
• Available HLA or family-donor information when clinically relevant
• Parent or legal-guardian identity and authorization

A Parent or Legal Guardian Can Start Case Review

The MedTransplant Case Review supports submission by a parent or legal guardian. The submitter should identify their relationship and confirm authorization while keeping the child’s information accurate and limited to what is relevant.

Conditioning, Infusion and Engraftment

After evaluation and a confirmed plan, the child may receive conditioning to prepare for transplantation. Stem cells are then infused through the treatment access selected by the clinical team. Blood counts may remain low while the team watches for engraftment and supports the child through the early recovery period.

The supplied donor-based offers describe engraftment estimates of approximately 10–25 days, but the actual course varies. Infection, delayed blood-count recovery, GVHD and other complications may alter monitoring, treatment and length of stay.

Monitoring During and After Admission

Monitoring can include blood counts, organ function, electrolytes, infection testing, medication levels and clinical examination. In allogeneic pathways, the hospital may also monitor chimerism—the proportion of blood-forming cells associated with the donor—and signs of GVHD.

Discharge depends on clinical stability rather than a calendar date. Outpatient visits and testing can continue for months, and complications may require a longer stay or renewed hospital care.

How MedTransplant Coordinates the Review

The family submits the child’s available records. MedTransplant organizes the case for an initial review or medical second-opinion pathway, coordinates an appropriate transplant-center evaluation, and relays requests for further records or HLA information.

If Acıbadem is selected, its pediatric specialists determine whether evaluation can progress and which pathway, if any, may be proposed. MedTransplant can coordinate the treatment plan and quotation, seek clarification of hospital charges, support appointment and travel planning, and help organize discharge and return communication. MedTransplant does not determine eligibility or select, source or provide donors.

Families May Compare Verified Programs

Families may explore other verified hospital programs or ask MedTransplant for a practical comparison. A responsible comparison considers pediatric expertise, review requirements, clinical fit and continuity—not unsupported superiority claims.

Planning Pediatric BMT Abroad

Wait for a meaningful preliminary response before non-refundable bookings. Length of stay can be substantial and varies by pathway and clinical course. A parent, guardian or family support person may need to remain with the child during admission and outpatient follow-up.

The supplied offers describe hospital stays measured in weeks, post-discharge monitoring in Türkiye and repeated outpatient assessments. Complications can extend treatment or stay. Accommodation may need to be arranged after discharge, and the documents explicitly place accommodation costs with the patient or accompanying family. Travel home depends on clinical stability and specialist approval—not an estimated date.

Current Costs Require an Individual Hospital Quotation

Pediatric BMT costs depend on transplant type, donor pathway or search, recipient and donor evaluation, conditioning, hospitalization, medicines, complications, additional treatment and length of stay. Current hospital costs should be confirmed after medical evaluation and selection of the appropriate transplant pathway.

The supplied documents contain historical package figures, but these are not published as current or starting prices. MedTransplant may request a current hospital treatment plan and quotation, seek clarification of charges and advocate for transparent, appropriate costs. Discounts or savings are never guaranteed.

Pediatric Follow-up Must Be Continuous

Before treatment, identify the local pediatric hematology team responsible after return. Infection monitoring, medicines, blood counts, immune recovery, vaccinations, growth and psychosocial support may require long-term coordination.